Principal Financial Group
APLT

Principal Financial Group’s Applied Therapeutics APLT Stock Holding History

Principal Financial Group’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,583
Closed -$54.1K – 2235
2024
Q2 		$54.1K Buy
+11,583
New +$54.8K ﹤0.01% 2271

Other funds holding APLT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Principal Financial Group's APLT Position: Q3 2024 in Review

Principal Financial Group sold out of Applied Therapeutics (APLT) in Q3 2024, closing a stake of 11,583 shares — an estimated $54.1K sold.

Principal Financial Group first reported a position in APLT in Q2 2024 and held it in 1 quarter. The position peaked at $54.1K in Q2 2024. 126 funds tracked by Wall St. Rank hold APLT as of Q3 2024.

  • Principal Financial Group reported no remaining Applied Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 11,583 Applied Therapeutics shares in Q3 2024, an estimated $54.1K.
  • Principal Financial Group first reported a position in Applied Therapeutics in Q2 2024 and held it in 1 quarter.
  • Principal Financial Group's Applied Therapeutics position peaked at $54.1K in Q2 2024.
  • 126 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.